Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-01-17, Stock:LLY, The news for the past five days is as follows:
2020-01-10: NEWS1: Biotechs punch up talking points leading into big Union Square conference.NEWS2: Eli Lilly Made a Deal for Dermira. The Biotech’s Stock Price Shows Investors Expect More..NEWS3: Stocks close lower after Dow briefly tops 29,000 milestone for first time.NEWS4: ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc..NEWS5: Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?.NEWS6: Eli Lilly to add eczema drug with $1.1 billion deal for Dermira.NEWS7: Eli Lilly, Apple, Yum! Brands, Nintendo: Companies to watch.NEWS8: Eli Lilly, Apple, Yum! Brands, Nintendo: Companies to Watch.NEWS9: Lilly Says It’s Buying a Biotech With a Dermatitis Drug. Investors Have Other Ideas..NEWS10: Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR.NEWS11: Eli Lilly Reports Deal To Buy Dermira For $1.1B.NEWS12: Eli Lilly to buy Dermira in a deal valued at $1.1 billion.NEWS13: Lilly Announces Agreement to Acquire Dermira.NEWS14: Eli Lilly to Buy Skin Treatment Company Dermira for $1.1 Billion.NEWS15: Pre-market Movers - Eli Lilley, Boeing in View.
2020-01-13: NEWS1: SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Dermira, Inc. - (Nasdaq:DERM).NEWS2: SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dermira, Inc. to Eli Lilly and Company is Fair to Shareholders.NEWS3: Glaxo Files Marketing Application for Fostemsavir in Europe.NEWS4: Company News for Jan 13, 2020.NEWS5: Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate.NEWS6: Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?.NEWS7: Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?.NEWS8: Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC.NEWS9: Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC.
2020-01-14: NEWS1: Eli Lilly ends deal with NextCure worth up to $1.4B for the local biotech.NEWS2: Eli Lilly Interested in Bolt-On Acquisitions, CEO Says.NEWS3: Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company.NEWS4: Big Merger Deals Are Missing at Health Conference. Here’s Why..NEWS5: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug.NEWS6: Eli Lilly to make two more cheaper insulin products available from mid-April.NEWS7: Lilly expands insulin affordability options with lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen®.
2020-01-15: NEWS1: Nektar's Pain Drug Gets Adverse Advisory Committee Decision.NEWS2: Democrats Called for Cuts to Drug Prices at the Debate. The Pharma Industry Says It’s Trying..NEWS3: Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins.NEWS4: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance.NEWS5: Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease.
2020-01-16: NEWS1: Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO.NEWS2: Eli Lilly (LLY) Gains But Lags Market: What You Should Know.NEWS3: Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement.NEWS4: FDA Risks Sacrificing Its Standards for Speed.NEWS5: J&J Seeks Label Expansion for Spravato Nasal Spray in EU.NEWS6: Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA.

Answer: Decrease